RxDoctor Payments Data

Richard Villaceran

Family · Wauconda, ILNPI 1245649862

Payments from drug & device makers

$8,254in general payments, 2019–2025

Across 431 payments — averaging $19.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • AstraZeneca$1K
  • Lilly USA, LLC$694
  • Bayer$584
  • Boehringer Ingelheim$354
  • Pfizer$312
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$8,254100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,254 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$54,609
Medicare patients
148
Services billed
1,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GlatopaGlatiramer Acetate12$56,621
JardianceEmpagliflozin53$45,008
MounjaroTirzepatide30$32,236
OzempicSemaglutide33$29,041
EliquisApixaban22$21,995
TrulicityDulaglutide20$21,136
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$18,988
FarxigaDapagliflozin Propanediol16$12,244
XareltoRivaroxaban13$9,378
Rosuvastatin Calcium108$2,846
Ezetimibe36$1,666
Albuterol Sulfate HfaAlbuterol Sulfate56$1,467
Gabapentin70$1,354
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$1,249
Atorvastatin Calcium125$1,210

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$694$53,37250 claims
Boehringer IngelheimJardiance$354$45,00853 claims
Novo NordiskOzempic$158$29,04133 claims
PfizerEliquis$312$21,99522 claims
GSKTrelegy Ellipta$277$18,98827 claims
AstraZenecaFarxiga$1,142$12,24416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Wauconda

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →